Apremilast for the treatment of moderate ‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

ConclusionDespite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate‐to‐severe palmoplantar psoriasis.

Source: Journal of the European Academy of Dermatology and Venereology - November 15, 2017 Category: Dermatology Authors: R. Bissonnette, R. Haydey, L.A. Rosoph, C.W. Lynde, M. Bukhalo, J.F. Fowler, I. Delorme, A. Gagn é‐Henley, M. Gooderham, Y. Poulin, K. Barber, P. Jenkin, I. Landells, D.M. Pariser Tags: Original Article Source Type: research